{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:15:44Z","timestamp":1760577344878,"version":"3.40.3"},"publisher-location":"New Delhi","reference-count":24,"publisher":"Springer India","isbn-type":[{"type":"print","value":"9788132217732"},{"type":"electronic","value":"9788132217749"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-81-322-1774-9_7","type":"book-chapter","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T07:11:09Z","timestamp":1393917069000},"page":"77-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nanonization Increases the Antileishmanial Efficacy of Amphotericin B: An Ex Vivo Approach"],"prefix":"10.1007","author":[{"given":"Krishna Das","family":"Manandhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thakur Prasad","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Kumar","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Om","family":"Basukala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram Prasad","family":"Aganja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Dude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onkar Nath","family":"Shrivastav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"key":"7_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/0169-4758(92)90249-2","volume":"8","author":"RW Ashford","year":"1992","unstructured":"Ashford RW, Desjeux P, Deraadt P (1992) Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol Today 8:104\u2013105","journal-title":"Parasitol Today"},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","volume":"27","author":"P Desjeux","year":"2004","unstructured":"Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27:305\u2013318","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"7_CR3","first-page":"62","volume":"12","author":"D Bora","year":"1999","unstructured":"Bora D (1999) Epidemiology of visceral leishmaniasis in India. Natl Med J India 12:62\u201368","journal-title":"Natl Med J India"},{"key":"7_CR4","unstructured":"Lal S, Saxena NBL, Dhillon GPS (1996) Kala-azar cases and deaths. In: manual on visceral leishmaniasis (kala-azar) in India. National Malarial Eradication Programme, Annexure VII, New Delhi, pp 167-77"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/clind\/24.4.684","volume":"24","author":"JD Berman","year":"1997","unstructured":"Berman JD (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10\u00a0years. Clin Infect Dis 24:684\u2013703","journal-title":"Clin Infect Dis"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1086\/318121","volume":"31","author":"S Sundar","year":"2000","unstructured":"Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31:1104\u20131107","journal-title":"Clin Infect Dis"},{"key":"7_CR7","first-page":"166","volume":"120","author":"CP Thakur","year":"2004","unstructured":"Thakur CP, Narayan S, Ranjan A (2004) Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 120:166\u2013172","journal-title":"Indian J Med Res"},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0035-9203(00)90277-3","volume":"94","author":"S Sundar","year":"2000","unstructured":"Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW (2000) Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg 94:200\u2013204","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","volume":"47","author":"RH Muller","year":"2001","unstructured":"Muller RH, Jacobs C, Kayser O (2001) Nanoparticles as particulate drug formulations in therapy rationale for development and what we can expect for future. Adv Drug Deliv Rev 47:3\u201319","journal-title":"Adv Drug Deliv Rev"},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1128\/AAC.45.8.2185-2197.2001","volume":"45","author":"HW Murray","year":"2001","unstructured":"Murray HW (2001) Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 45:2185\u20132197","journal-title":"Antimicrob Agents Chemother"},{"key":"7_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s004300100084","volume":"190","author":"K Muller","year":"2001","unstructured":"Muller K, van Zandbergen G, Hansen B, Laufs H, Jahnke N, Solbach W, Laskay T (2001) Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice. Med Microbiol Immunol 190:73\u201376","journal-title":"Med Microbiol Immunol"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nature00985","volume":"419","author":"A Calka","year":"2001","unstructured":"Calka A, Wexler D (2001) Mechanical milling assited by electrical discharge. Nature 419:147\u2013151","journal-title":"Nature"},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0169-409X(00)00117-4","volume":"47","author":"K Yoshiaki","year":"2001","unstructured":"Yoshiaki K (2001) Nanoparticulate systems for improved drug delivery. Adv Drug Deliv Rev 47:1\u20132","journal-title":"Adv Drug Deliv Rev"},{"key":"7_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1389201053167158","volume":"6","author":"O Kayser","year":"2005","unstructured":"Kayser O, Lemke A, Hernandez-Trejo N (2005) The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 6:3\u20135","journal-title":"Curr Pharm Biotechnol"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrd1494","volume":"3","author":"BE Rabinow","year":"2004","unstructured":"Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discovery 3:785\u2013796","journal-title":"Nat Rev Drug Discovery"},{"key":"7_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/infdis\/jir735","volume":"205","author":"VK Prajapati","year":"2011","unstructured":"Prajapati VK, Awasthi K, Yadav TP, Rai M, Srivastava ON, Sundar S (2011) An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis 205:333\u2013336","journal-title":"J Infect Dis"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/jac\/dkr002","volume":"66","author":"VK Prajapati","year":"2011","unstructured":"Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S (2011) Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother 66:874\u2013879","journal-title":"J Antimicrob Chemother"},{"key":"7_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/jac\/dkn189","volume":"62","author":"KD Manandhar","year":"2008","unstructured":"Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S (2008) Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother 62:376\u2013380","journal-title":"J Antimicrob Chemother"},{"key":"7_CR19","first-page":"427","volume":"59","author":"MM Bunn-Moreno","year":"1985","unstructured":"Bunn-Moreno MM, Madeira ED, Miller K, Menezes JA, Campos-Neto A (1985) Hypergammaglobulinaemia in Leishmania donovani infected hamsters: possible association with a polyclonal activator of B cells and with suppression of T cell function. Clin Exp Immunol 59:427\u2013434","journal-title":"Clin Exp Immunol"},{"key":"7_CR20","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.4049\/jimmunol.134.4.2713","volume":"134","author":"ED Franke","year":"1985","unstructured":"Franke ED, McGreevy PB, Katz SP, Sacks DL (1985) Growth cycle-dependent generation of complement-resistant Leishmania promastigotes. J Immunol 134:2713\u20132718","journal-title":"J Immunol"},{"key":"7_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0924-8579(99)00133-8","volume":"13","author":"V Yardley","year":"2000","unstructured":"Yardley V, Croft SL (2000) A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 13:243\u2013248","journal-title":"Int J Antimicrob Agents"},{"key":"7_CR22","first-page":"439","volume":"89","author":"S Bhatnagar","year":"1989","unstructured":"Bhatnagar S, Guru PY, Katiyar JC, Srivastava R, Mukherjee A, Akhtar MS, Seth M, Bhaduri AP (1989) Exploration of antileishmanial activity in heterocycles; results of their in vivo and in vitro bioevaluations. Indian J Med Res 89:439\u2013444","journal-title":"Indian J Med Res"},{"key":"7_CR23","unstructured":"ScienceDaily (2011) New treatment for Kala Azar, the most deadly parasitic disease after malaria. http:\/\/www.sciencedaily.com\/releases\/2011\/09\/110923102525.htm. Accessed 23 Mar 2012"},{"key":"7_CR24","doi-asserted-by":"publisher","first-page":"e1000813","DOI":"10.1371\/journal.ppat.1000813","volume":"6","author":"R Phillips","year":"2010","unstructured":"Phillips R, Svensson M, Aziz N, Maroof A, Brown N, Beattie L, Signoret N, Kaye PM (2010) Innate killing of Leishmania donovani by macrophages of the splenic marginal zone requires IRF-7. PLoS Pathog 6:e1000813","journal-title":"PLoS Pathog"}],"container-title":["Advances in Experimental Medicine and Biology","Infectious Diseases and Nanomedicine II"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-81-322-1774-9_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T23:12:44Z","timestamp":1675984364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-81-322-1774-9_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9788132217732","9788132217749"],"references-count":24,"URL":"https:\/\/doi.org\/10.1007\/978-81-322-1774-9_7","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2014]]},"assertion":[{"value":"5 March 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}